Literature DB >> 33647883

Mucosal microRNAs relate to age and severity of disease in ulcerative colitis.

Mikkel Malham1,2, Jaslin P James3,4, Christian Jakobsen1, Estrid Hoegdall3, Kim Holmstroem4, Vibeke Wewer1, Boye S Nielsen4, Lene B Riis3.   

Abstract

Despite significant evidence that the expression of several microRNAs (miRNAs) impacts disease activity in patients with ulcerative colitis (UC), it remains unknown if the more severe disease phenotype seen in pediatric onset UC can be explained by an altered miRNA expression. In this study, we assessed the relationship between miRNA expression, age, and disease severity in pediatric and adult patients with UC. Using RT-qPCR, we analyzed the expression of miR-21, miR-31, miR-126, miR-142 and miR-155 in paraffin embedded rectum biopsies from 30 pediatric and 30 adult-onset UC patients. We found that lesions from adult patients had significantly higher expression levels of miR-21 compared to pediatric patients and that the expression levels of miR-31 (all patients) and miR-155 (pediatric patients only) correlated inversely with histological assessed disease severity. Using in situ hybridization followed by image analysis, the expression level estimates of miR-21 and miR-126 correlated with histological assessed disease severity. In conclusion, we found that the expression of miRNAs depends on the age of the patient and/or the severity of the disease, suggesting that miRNAs may contribute to the regulation of inflammation in UC and could be useful biomarkers in the surveillance of disease severity.

Entities:  

Keywords:  in situ hybridization; inflammatory bowel disease; miRNA; pediatric; quantitative polymerase chain reaction

Mesh:

Substances:

Year:  2021        PMID: 33647883      PMCID: PMC7993741          DOI: 10.18632/aging.202715

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  65 in total

1.  miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses.

Authors:  Udai P Singh; Angela E Murphy; Reilly T Enos; Haidar A Shamran; Narendra P Singh; Honbing Guan; Venkatesh L Hegde; Daping Fan; Robert L Price; Dennis D Taub; Manoj K Mishra; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

2.  MicroRNA-126 inhibits cell viability and invasion in a diabetic retinopathy model via targeting IRS-1.

Authors:  Shifeng Fang; Xiang Ma; Suping Guo; Jianmin Lu
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

3.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

4.  Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation.

Authors:  Alexandru V Olaru; Florin M Selaru; Yuriko Mori; Christine Vazquez; Stefan David; Bogdan Paun; Yulan Cheng; Zhe Jin; Jian Yang; Rachana Agarwal; John M Abraham; Themistocles Dassopoulos; Mary Harris; Theodore M Bayless; John Kwon; Noam Harpaz; Ferenc Livak; Stephen J Meltzer
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

5.  MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis.

Authors:  Florian Meisgen; Ning Xu; Tianling Wei; Peter C Janson; Susanna Obad; Oliver Broom; Nikoletta Nagy; Sakari Kauppinen; Lajos Kemény; Mona Ståhle; Andor Pivarcsi; Enikö Sonkoly
Journal:  Exp Dermatol       Date:  2012-04       Impact factor: 3.960

6.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.

Authors:  K Geboes; R Riddell; A Ost; B Jensfelt; T Persson; R Löfberg
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

7.  MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha.

Authors:  Feng Wu; Michelle Zikusoka; Anil Trindade; Themistocles Dassopoulos; Mary L Harris; Theodore M Bayless; Steven R Brant; Shukti Chakravarti; John H Kwon
Journal:  Gastroenterology       Date:  2008-08-03       Impact factor: 22.682

Review 8.  microRNAs: small molecules with big roles - C. elegans to human cancer.

Authors:  Masaomi Kato; Frank J Slack
Journal:  Biol Cell       Date:  2008-02       Impact factor: 4.458

9.  miR-155 targets Est-1 and induces ulcerative colitis via the IL-23/17/6-mediated Th17 pathway.

Authors:  Jiangtao Hou; Xueying Hu; Bin Chen; Xu Chen; Lina Zhao; Zhuoqun Chen; Fengbin Liu; Zhihui Liu
Journal:  Pathol Res Pract       Date:  2017-08-25       Impact factor: 3.250

10.  Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.

Authors:  Johan Van Limbergen; Richard K Russell; Hazel E Drummond; Marian C Aldhous; Nicola K Round; Elaine R Nimmo; Linda Smith; Peter M Gillett; Paraic McGrogan; Lawrence T Weaver; W Michael Bisset; Gamal Mahdi; Ian D Arnott; Jack Satsangi; David C Wilson
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682

View more
  2 in total

Review 1.  miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis.

Authors:  Jing Zhou; Jialing Liu; Yangyang Gao; Liwei Shen; Sheng Li; Simin Chen
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

2.  Global trends in research on miRNA-microbiome interaction from 2011 to 2021: A bibliometric analysis.

Authors:  Xiang-Yun Yan; Jun-Peng Yao; Yan-Qiu Li; Wei Zhang; Meng-Han Xi; Min Chen; Ying Li
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.